Vivoryon Therapeutics N.V. — AGM Information 2019

Apr 18, 2019

Probiodrug AG

WKN: 792183 ISIN: DE0007921835 Land: Deutschland

Nachricht vom 18.04.2019 | 15:06

Probiodrug AG: Probiodrug AG to hold its Ordinary General Meeting of Shareholders on 29 May 2019

DGAP-News: Probiodrug AG / Key word(s): AGM/EGM

18.04.2019 / 15:06 The issuer is solely responsible for the content of this announcement.

Probiodrug AG to hold its Ordinary General Meeting of Shareholders on 29 May 2019

HALLE (SAALE), Germany, 18 April 2019 - Probiodrug AG (Euronext Amsterdam: PBD; ISIN: DE0007921835), invites all shareholders to Probiodrugs ordinary general meeting of shareholders to be held on Thursday, May 29, 2019 at 10:00 am (CEST), at the registered office, Weinbergweg 22, 06120 Halle (Saale), Germany.

The relevant documents can be found at the company's homepage: www.probiodrug.de/investors/ ordinary-general-meeting-of-shareholders-2019/

For more information, please contact:

Probiodrug Dr. Ulrich Dauer, CEO Email: contact@probiodrug.com

MC Services AG

Anne Hennecke, Susanne Kutter Tel: +49 (0) 211 529 252 27 Email: probiodrug@mc-services.eu

Notes to Editors: About Probiodrug AG

Headquartered in Halle (Saale), Germany, Probiodrug AG (Euronext Amsterdam: PBD) is a clinical stage biopharmaceutical company focused on the development of novel inhibitors for disease relevant enzymes. The company has a successful track record in bringing drugs targeted to posttranslational modifying enzymes to the market. Current projects are focusing on the two isoenzymes of Glutaminyl Cyclase, QPCT and QPCTL. QPCT is the crucial enzyme for the generation of highly neurotoxic pyroglutamate species of Abeta. Its inhibition by Probiodrug's lead molecule PQ912 is currently investigated in clinical Phase 2 trials (SAPHIR) for the treatment of Alzheimer's disease (AD). Whereas QPCTL has been identified as a potential target in cancer therapy. Blocking the enzymatic function of QPTCL by small molecule inhibitors is a novel therapeutic approach in cancer immunotherapy. Probiodrug has a unique and exceptionally strong patent position on QPCT and QPCTL inhibitors. www.probiodrug.com

About PQ912

PQ912, is a first in class, highly specific and potent inhibitor of Glutaminyl Cyclase (QPCT), the enzyme that catalyses the formation of highly neurotoxic pGlu species. PQ912 has shown therapeutic effects in AD animal models. A Phase-1 study in healthy young and elderly volunteers revealed a dose dependent exposure and showed good safety and tolerability up to the highest dose resulting in >90% target occupancy in the spinal fluid. In June 2017, Probiodrug announced top-line data of the Phase-2a SAPHIR trial of PQ912 and presented the study results at CTAD 2017. Results strongly support that pGlu species of Abeta are especially neurotoxic and

correlate with AD disease progression. The SAPHIR study provides important guidance how to move forward with the development of PQ912 as a disease-modifying drug for AD. Altogether, the results make the program highly attractive for further development; the company has initiated the preparation of a Phase 2b core program. Probiodrug AG: Probiodrug AG to hold its Ordinary General Meeting of... https://www.dgap.de/dgap/News/corporate/probiodrug-probiodrug-hold-i...

About Alzheimer's disease

Alzheimer's disease is a neurological disorder, which is the most common form of dementia. Today, 50 million people live with dementia worldwide, and this number is projected to treble to more than 152 million by 2050. Dementia also has a huge economic impact. Alzheimer's has an estimated, global societal cost of US\$ 1 trillion, and it will become 2 trillion-dollar disease by 2030. (World Alzheimer Report 2018).

Glutaminyl-peptide cyclotransferase-like protein (QPCTL)

Glutaminyl-peptide cyclotransferase-like protein (QPCTL) is a posttranslational modifying enzyme that is responsible for the pyroglutamate formation on crucial proteins in the immune response to cancer.

Cancer immune checkpoint inhibitors

Checkpoint inhibitor therapy is a novel kind of cancer immunotherapy. The therapy targets immune checkpoints, key regulators of the immune system that stimulate or inhibit its actions, which tumors can use to protect themselves from attacks by the immune system. QPCTL inhibitor therapy can block inhibitory cancer checkpoints and thereby restore beneficial immune system functions.

Forward Looking Statements

Forward Looking Statements Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Probiodrug AG as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to
reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.
18.04.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Archive at www.dgap.de
English Probiodrug AG Weinbergweg 22 06120 Halle/Saale Germany
+49 (0)345 555 9900 +49 (0)345 555 9901
contact@probiodrug.de www.probiodrug.de DE0007921835 792183
Regulated Unofficial Market in Berlin, Frankfurt, Munich, Stuttgart; Amsterdam 801885
DGAP News Service